8-K
Current Report
BioXcel Therapeutics, Inc. Filed Acc 0001104659-24-101176
Exit or restructuring costs · Executive or director change
- Item 2.05 Costs associated with exit or disposal activities
- Item 5.02 Departure or appointment of directors or officers
From the SEC's structured data for this filing
Loading tm2424352d2_8k.htm…